IVP方案治疗61例进展期非小细胞肺癌临床疗效  

Efficacy analysis of IVP chemotherapy in 61 patients with advanced non-small cell lung cancer

作　　者：单利[1] 唐勇[1] 姜家豫[1] 

机构地区：[1]新疆医科大学附属肿瘤医院内科,新疆乌鲁木齐830011

出　　处：《新疆医科大学学报》2001年第3期233-234,共2页Journal of Xinjiang Medical University

摘　　要：目的:观察 IVP方案治疗进展期非小细胞肺癌 (NSCL C)的临床疗效和毒性。 方法:选择 6 1例晚期NSCL C患者 ,行 IVP方案化疗 (IFO2 g静点 ,第 1～ 5天 ;DDP5 0 m g静点 ,第 1～ 3天 ;VDS4m g静注 ,第 1天和第 8天 ;2 1d为一周期 )。评价其疗效和毒性 ,并进行随访。结果 :总有效率为 45 .9% ,完全缓解率为 3.3% ,白细胞减少发生率 95 .1% ( ～ 度为 2 9.5 % ) ,无相关死亡。结论 :IVP方案治疗进展期 NSCL C疗效较好 。Objective: To observe and evaluate the efficacy and toxicity of IVP regime on advanced non small cell lung cancer. Method: Between March 1996 and December 1998,61 patients with advanced non small cell lung cancer were treated with IFO 2 g/day for 5 consecutive days by intravenous infusion(IV),DDP 50 mg/day for 3 consecutive days IV,VDS 4 mg/day for 1st and 8th day IV,every 3 weeks. Results: The overall response rate was 45.9% and the complete response rate was 3.3%. Leukopenia was observed in 95.1% of the patients, in which grade 3～4 toxicity were in 29.5% of patients. Anemia and thrombocytopenia were observed in 70.5% and 49.2%. Conclusions: IVP(IFO,DDP and VDS)are effective on advanced NSCLC,it is worthy to be further studied.

关 键 词：IVP方案 非小细胞肺癌 化疗 NSCLC 

分 类 号：R734.2[医药卫生—肿瘤] R730.53[医药卫生—临床医学]